Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.

Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Polakova KM.

Haematologica. 2018 Dec;103(12):2016-2025. doi: 10.3324/haematol.2018.193086. Epub 2018 Jul 26.

2.

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia.

Šmahelová J, Kaštánková I, Poláková KM, Klamová H, Zemanová K, Tachezy R, Hamšíková E, Šmahel M.

Oncol Rep. 2017 Jan;37(1):547-554. doi: 10.3892/or.2016.5226. Epub 2016 Nov 7.

PMID:
27840977
3.

Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.

Toman O, Kabickova T, Vit O, Fiser R, Polakova KM, Zach J, Linhartova J, Vyoral D, Petrak J.

Oncol Rep. 2016 Sep;36(3):1258-68. doi: 10.3892/or.2016.4945. Epub 2016 Jul 18.

4.

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.

Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G.

Oncotarget. 2016 Apr 19;7(16):21982-90. doi: 10.18632/oncotarget.8010.

5.

Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.

Soverini S, De Benedittis C, Papayannidis C, Polakova KM, Venturi C, Russo D, Bresciani P, Iurlo A, Mancini M, Vitale A, Chiaretti S, Foà R, Abruzzese E, Sorà F, Kohlmann A, Haferlach T, Baccarani M, Cavo M, Martinelli G.

Leukemia. 2016 Jul;30(7):1615-9. doi: 10.1038/leu.2016.17. Epub 2016 Feb 12. No abstract available.

PMID:
26867670
6.

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR.

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedéu J, Nymoen DA, Leibundgut EO, Ozbek U, Pajič T, Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VH, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, Müller MC, Hochhaus A, Schimmel H, Cross NC, Emons H.

Leukemia. 2015 Feb;29(2):369-76. doi: 10.1038/leu.2014.217. Epub 2014 Jul 18.

7.

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.

Racil Z, Razga F, Klamova H, Voglova J, Belohlavkova P, Malaskova L, Potesil D, Muzik J, Zackova D, Polakova KM, Zdrahal Z, Malakova J, Suttnar J, Dyr J, Mayer J.

Hematol Oncol. 2014 Jun;32(2):87-93. doi: 10.1002/hon.2091. Epub 2013 Aug 20. Erratum in: Hematol Oncol. 2014 Sep;32(3):168.

PMID:
23963760
8.

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.

Klamová H, Poláková KM, Mužík J, Ráčil Z, Záčková D, Steinerová K, Karas M, Faber E, Demečková E, Michalovičová-Sninská Z, Voglová J, Demitrovičová L, Mikušková E, Tóthová E, Chudej J, Markuljak I, Cmunt E, Moravcová J, Dvořáková D, Michalová K, Jarošová M, Sťastná MM, Cetkovský P, Dušek L, Koza V, Trněný M, Indrák K.

Cancer Med. 2013 Apr;2(2):216-25. doi: 10.1002/cam4.59. Epub 2013 Feb 21.

9.

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

Zackova D, Klamova H, Dusek L, Muzik J, Polakova KM, Moravcova J, Jurcek T, Dvorakova D, Racil Z, Pospisil Z, Oltova A, Michalova K, Brezinova J, Razga F, Doubek M, Cetkovsky P, Trneny M, Mayer J.

Am J Hematol. 2011 Mar;86(3):318-21. doi: 10.1002/ajh.21942. Epub 2011 Feb 15. No abstract available.

10.

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

Racil Z, Razga F, Polakova KM, Buresova L, Polivkova V, Dvorakova D, Zackova D, Klamova H, Cetkovsky P, Mayer J.

Leuk Lymphoma. 2011 Feb;52(2):331-4. doi: 10.3109/10428194.2010.533220. Epub 2010 Dec 6. No abstract available.

PMID:
21133723
11.

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.

Poláková KM, Polívková V, Rulcová J, Klamová H, Jurcek T, Dvoráková D, Zácková D, Pospísil Z, Mayer J, Moravcová J.

Exp Hematol. 2010 Jan;38(1):20-6. doi: 10.1016/j.exphem.2009.10.003.

PMID:
19837125
12.

Control genes in international standardization of real-time RT-PCR for BCR-ABL.

Moravcová J, Rulcová J, Poláková KM, Klamová H.

Leuk Res. 2009 Apr;33(4):582-4. doi: 10.1016/j.leukres.2008.06.020. Epub 2008 Jul 23. No abstract available.

PMID:
18653236
13.

BCR-ABL mutations in chronic myeloid leukemia - not only detection.

Polakova KM, Zmekova V, Rulcova J, Klamova H, Zemanova Z, Moravcova J.

Leuk Lymphoma. 2008 Aug;49(8):1620-2. doi: 10.1080/10428190802105074. No abstract available.

PMID:
18452092
14.

High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain.

Poláková KM, Lopotová T, Klamová H, Moravcová J.

Leuk Res. 2008 Aug;32(8):1236-43. doi: 10.1016/j.leukres.2008.01.010. Epub 2008 Mar 4.

PMID:
18308387
15.

Coding region single nucleotide polymorphism in the barley low-pI, alpha-amylase gene Amy32b.

Polakova KM, Kucera L, Laurie DA, Vaculova K, Ovesna J.

Theor Appl Genet. 2005 May;110(8):1499-504. Epub 2005 Apr 5.

PMID:
15809849

Supplemental Content

Loading ...
Support Center